期刊
CURRENT PHARMACEUTICAL DESIGN
卷 24, 期 22, 页码 2549-2555出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612824666180803112304
关键词
Circadian rhythm; depression; melatonin; melatonin receptor agonists; pharmacology; antidepressants
资金
- Ministry of Science and Technology, Taiwan [MOST 106-2314-B-038-049, 106-2314-B-039-027-MY3, 106-2314-B-038-049, 106-2314-B-039-031, 106-2314-B-039-035, 104-2314-B-039-022-MY2, 104-2314-B-039-050-MY3]
- National Health Research Institutes, Taiwan [NHRI-EX105-10528NI]
- China Medical University, Taiwan [DMR-107-202, DMR-107-204]
- Chinese Medicine Research Center from the China Medical University, Taiwan
Background: Circadian rhythm disruption underlies the pathophysiology of psychiatric disorders, especially depression. Both pharmacological and non-pharmacological strategies affecting endogenous circadian rhythms have been developed with specificity to alter the circadian dysfunction. The current management strategy with antidepressants is far from being satisfactory in addressing this issue. In recent years, attempts at discovering new antidepressants focused on a melatonergic system which is known to be altered in depression have led to a potential option for treatment of depression. Methods: We reviewed all recently published relevant articles on melatonin and its analogues to look for their implication in the treatment of circadian rhythm disruption and depression. Results: Melatonin, a pleiotropic regulator molecule and its analogues (ramelteon, agomelatine, TIK-301, Neu-P11 and tasimelteon) have been observed to resynchronize the circadian rhythm and some were said to alleviate depressive symptoms in depressed subjects. Conclusion: This review focuses on substantial advances in the melatonin-based chronobiologic intervention and its responses in the treatment of depression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据